In the latest trading session, 4.7 million Immunovant Inc (NASDAQ:IMVT) shares changed hands as the company’s beta touched 0.77. With the company’s most recent per share price at $20.25 changing hands around $1.46 or 7.76% at last look, the market valuation stands at $3.44B. IMVT’s current price is a discount, trading about -77.63% off its 52-week high of $35.97. The share price had its 52-week low at $17.65, which suggests the last value was 12.84% up since then. When we look at Immunovant Inc’s average trading volume, we note the 10-day average is 1.05 million shares, with the 3-month average coming to 1.22 million.
Analysts gave the Immunovant Inc (IMVT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 1 out of 20 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended IMVT as a Hold, 13 felt it is a Buy and 0 rated the stock as Underweight. Immunovant Inc’s EPS for the current quarter is expected to be -0.72.
Immunovant Inc (NASDAQ:IMVT) trade information
Instantly IMVT is in green as seen in intraday trades today. With action 5.90%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -18.26%, with the 5-day performance at 5.90% in the green. However, in the 30-day time frame, Immunovant Inc (NASDAQ:IMVT) is -2.75% down. Looking at the short shares, we see there were 15.39 million shares sold at short interest cover period of 11.25 days.
The consensus price target for the stock as assigned by Wall Street analysts is 49, meaning bulls need an upside of 58.67% from its recent market value. According to analyst projections, IMVT’s forecast low is 5 with 57 as the target high. To hit the forecast high, the stock’s price needs a -181.48% plunge from its current level, while the stock would need to tank 75.31% for it to hit the projected low.
Immunovant Inc (IMVT) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%. The 2025 estimates are for Immunovant Inc earnings to decrease by -49.95%, but the outlook for the next 5-year period is at -20.98% per year.
Immunovant Inc (NASDAQ:IMVT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 58.08% of Immunovant Inc shares while 47.58% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 113.49%. There are 47.58% institutions holding the Immunovant Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 7.5915% of the shares, roughly 10.48 million IMVT shares worth $276.77 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.7138% or 6.51 million shares worth $171.86 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. With 3.48 shares estimated at $70.5 million under it, the former controlled 2.05% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 1.22% of the shares, roughly 2.08 shares worth around $42.13 million.
